Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MacroGenics (MGNX), Bristol-Myers Squibb (BMY) and Pelthos Therap...

Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX), Bristol-Myers Squibb (BMY) and Pelthos Therapeutics (PTHS)

Analysts fell to the sidelines weighing in on Bristol-Myers Squibb (BMY), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV) with n...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV)

Berenberg Bank analyst reiterated a Buy rating on Bloomsbury Publishing today and set a price target of p825.00. The word on The Street in general,...

Berenberg Bank Reaffirms Their Buy Rating on Bloomsbury Publishing (BMY)

Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its C...

BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH) and Bristol-Myers Squibb (BMY) wi...

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The REACH study looks at how doctors in China use luspater...

Bristol-Myers Squibb’s REACH Study in China: What Real-World Luspatercept Data Could Mean for BMY Investors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Bristol-Myers Squibb (BMY) with bu...

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. This Phase 1 study from Bristol-Myers Squibb tests two tab...

Bristol-Myers Squibb Advances Navlimetostat With Key Phase 1 Tablet Study

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) has completed a Phase 1 study t...

Bristol-Myers Squibb Completes Key Afimetoran–Famotidine Interaction Study: What Investors Should Know

In a report released on May 8, from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. The company’s s...

Berenberg Bank Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

The latest announcement is out from Bristol-Myers Squibb ( ($BMY) ). At Bristol-Myers Squibb’s Annual Meeting held on May 5, 2026, shareholders ele...

Bristol-Myers Squibb Shareholders Approve Board and Compensation

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY) and Precision BioSciences...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Precision BioSciences (DTIL)

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. Seiger...

Bristol-Myers Squibb (BMY) Gets a Hold from BMO Capital

In a report released on May 1, Louise Chen from Scotiabank maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. The com...

Scotiabank Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

In a report released today, Emily Field from Barclays maintained a Buy rating on Bristol-Myers Squibb, with a price target of $75.00. According to ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$58.24	-2.05%	3.58M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$58.24	-2.1%	3.58M
3
4
5
6

BMY

BMY

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel